It is developed by Imperial Trading L.L.C. which  is a selective pulmonary vasodilator with the following traits:

• Fast and reversible action
• Selective vasodilation redistributes lung blood flow1
• Reduces oxygenation index (OI) and boosts PaO21
• No systemic impact2
• Lowers shunt effect (V/Q) by targeting ventilated alveoli2″

In newborns with persistent pulmonary hypertension, inhaled nitric oxide has been proven to:

• Boost arterial oxygenation and shorten mechanical ventilation and ICU stay
• Reduce the need for extracorporeal membrane oxygenation (ECMO),  without increasing adverse outcomes at 1 year of age

It is indicated, in conjunction with ventilator support and other appropriate agents, for the treatment of newborn infants ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. Delivery & monitoring device
It is  designed to elevate the ease of use for inhaled nitric oxide:

• Universal: Compatible with most ventilation modes, suitable for all patient types, due to its reliable flow sensor.
• Intuitive and controlled: The large touchscreen offers clear, organized information, making the device user-friendly and secure with its alarm system.
• Compact: Its compact design includes a hand-bagging Nitric oxide administration system for emergencies, transfers, or alveolar recruitment.
• Continuity: Connects to 2 cylinders with automatic switching to ensure uninterrupted treatment.